Home / Business and Economy / Cipla Facility Faces USFDA Scrutiny With 7 Observations
Cipla Facility Faces USFDA Scrutiny With 7 Observations
25 Aug
Summary
- USFDA inspected Cipla's Pithampur facility from August 17-25.
- Seven observations were issued by the US drug regulator.
- Cipla committed to addressing the observations within the timeline.
The US Food and Drug Administration (USFDA) has issued seven observations following an eight-day inspection of Cipla's Pithampur manufacturing facility. This follow-up inspection, conducted from August 17 to August 25, focused on current Good Manufacturing Practices (cGMP).
The observations were documented on a USFDA Form 483, which identifies conditions potentially violating regulatory requirements. Cipla has announced its intention to respond to these observations within the designated timeframe.
While the specific nature of the seven observations has not been disclosed by Cipla, the company's prompt response and the USFDA's subsequent assessment will be key developments. For Indian pharmaceutical companies, adherence to USFDA regulations is critical for maintaining supply and approvals in the US market.
